The Latest Breaking News from Biogen

The market rally held up despite hot inflation data. Boeing led new buys while Tesla ran higher. Airbnb soared late on earnings.

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

The FDA approved lecanemab, which has shown to slow the progression of Alzheimer's disease.

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

Biogen stock jumped late Friday after the Food and Drug Administration approved its second Alzheimer's treatment, now called Leqembi.

There's a large pipeline of promising yet expensive drugs that could get approved.

Eli Lilly is the IBD Stock Of The Day as the company explores new methods of treating Alzheimer's and obesity, driving LLY stock near highs.

U.S. health officials’ approval process for Biogen Inc.’s controversial Alzheimer’s drug was “rife with irregularities,” raising serious concerns about protocol lapses at the agency, congressional investigators said.